XTX Topco Ltd Takes $314,000 Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

XTX Topco Ltd bought a new position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 16,828 shares of the company’s stock, valued at approximately $314,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Lazard Asset Management LLC acquired a new stake in shares of Kiniksa Pharmaceuticals during the first quarter worth about $71,000. Ashton Thomas Private Wealth LLC acquired a new stake in Kiniksa Pharmaceuticals during the 2nd quarter worth approximately $100,000. China Universal Asset Management Co. Ltd. boosted its position in Kiniksa Pharmaceuticals by 88.1% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 7,708 shares of the company’s stock valued at $152,000 after buying an additional 3,611 shares during the period. Arizona State Retirement System acquired a new position in shares of Kiniksa Pharmaceuticals in the second quarter worth $209,000. Finally, Bayesian Capital Management LP purchased a new stake in shares of Kiniksa Pharmaceuticals during the first quarter worth $222,000. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

KNSA has been the subject of several analyst reports. Jefferies Financial Group assumed coverage on Kiniksa Pharmaceuticals in a research note on Friday, September 13th. They set a “buy” rating and a $40.00 target price for the company. Wedbush upped their target price on shares of Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 23rd. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Kiniksa Pharmaceuticals has a consensus rating of “Buy” and an average price target of $33.60.

Kiniksa Pharmaceuticals Stock Performance

Shares of NASDAQ KNSA opened at $23.96 on Friday. The stock’s 50-day simple moving average is $25.41 and its 200-day simple moving average is $21.33. The firm has a market capitalization of $1.71 billion, a PE ratio of 217.84 and a beta of 0.33. Kiniksa Pharmaceuticals, Ltd. has a fifty-two week low of $14.12 and a fifty-two week high of $27.92.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, July 23rd. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.03. The business had revenue of $108.30 million during the quarter, compared to the consensus estimate of $90.60 million. Kiniksa Pharmaceuticals had a negative net margin of 3.10% and a negative return on equity of 7.79%. The company’s revenue was up 51.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.02) EPS. On average, sell-side analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.29 earnings per share for the current fiscal year.

Insider Activity at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,500 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $26.91, for a total transaction of $470,925.00. Following the transaction, the chief operating officer now owns 119,911 shares of the company’s stock, valued at $3,226,805.01. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, COO Eben Tessari sold 17,500 shares of the company’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $26.91, for a total value of $470,925.00. Following the completion of the sale, the chief operating officer now directly owns 119,911 shares of the company’s stock, valued at approximately $3,226,805.01. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider John F. Paolini sold 22,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $26.32, for a total value of $579,040.00. Following the transaction, the insider now owns 47,803 shares in the company, valued at approximately $1,258,174.96. The disclosure for this sale can be found here. Insiders sold a total of 278,064 shares of company stock valued at $7,165,254 over the last ninety days. Insiders own 54.57% of the company’s stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.